Cargando…

Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report

BACKGROUND: Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare malignant tumor, and many patients with HAL exhibit high levels of alpha-fetoprotein (AFP) expression. Currently, there is no standardized treatment strategy for advanced HAL and its prognosis is poor. CASE SUMMARY: We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Su-Zhen, Zhang, Xiao-Chen, Jiang, Qi, Chen, Ming, He, Meng-Ye, Shen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561556/
https://www.ncbi.nlm.nih.gov/pubmed/36246828
http://dx.doi.org/10.12998/wjcc.v10.i28.10236
_version_ 1784807971425878016
author Xu, Su-Zhen
Zhang, Xiao-Chen
Jiang, Qi
Chen, Ming
He, Meng-Ye
Shen, Peng
author_facet Xu, Su-Zhen
Zhang, Xiao-Chen
Jiang, Qi
Chen, Ming
He, Meng-Ye
Shen, Peng
author_sort Xu, Su-Zhen
collection PubMed
description BACKGROUND: Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare malignant tumor, and many patients with HAL exhibit high levels of alpha-fetoprotein (AFP) expression. Currently, there is no standardized treatment strategy for advanced HAL and its prognosis is poor. CASE SUMMARY: We report a 55-year-old man with unresectable AFP-related HAL. The largest cross-sectional area of the mass in the upper lobe of the left lung at the beginning of treatment was 8.46 cm × 6.53 cm. The patient’s serum AFP level was 9283 ng/mL. The mass increased in size to 8.86 cm × 8.21 cm after two courses of platinum-based combination chemotherapy and immunotherapy, and serum AFP reached its highest level (71232.2 ng/mL). The patient was treated with sorafenib (400 mg twice daily, per os). Forty days later, the mass was reduced to 5.63 cm × 5.29 cm and serum AFP level dropped to 786.8 ng/mL. The patient achieved partial remission for > 9 mo with sorafenib and an excellent biomarker response, as well as survival > 13 mo, which is among the longest reported for unresectable stage IV HAL. CONCLUSION: This is the first report to document successful treatment of unresectable AFP-related HAL with single-agent sorafenib after multiline therapy.
format Online
Article
Text
id pubmed-9561556
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-95615562022-10-15 Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report Xu, Su-Zhen Zhang, Xiao-Chen Jiang, Qi Chen, Ming He, Meng-Ye Shen, Peng World J Clin Cases Case Report BACKGROUND: Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare malignant tumor, and many patients with HAL exhibit high levels of alpha-fetoprotein (AFP) expression. Currently, there is no standardized treatment strategy for advanced HAL and its prognosis is poor. CASE SUMMARY: We report a 55-year-old man with unresectable AFP-related HAL. The largest cross-sectional area of the mass in the upper lobe of the left lung at the beginning of treatment was 8.46 cm × 6.53 cm. The patient’s serum AFP level was 9283 ng/mL. The mass increased in size to 8.86 cm × 8.21 cm after two courses of platinum-based combination chemotherapy and immunotherapy, and serum AFP reached its highest level (71232.2 ng/mL). The patient was treated with sorafenib (400 mg twice daily, per os). Forty days later, the mass was reduced to 5.63 cm × 5.29 cm and serum AFP level dropped to 786.8 ng/mL. The patient achieved partial remission for > 9 mo with sorafenib and an excellent biomarker response, as well as survival > 13 mo, which is among the longest reported for unresectable stage IV HAL. CONCLUSION: This is the first report to document successful treatment of unresectable AFP-related HAL with single-agent sorafenib after multiline therapy. Baishideng Publishing Group Inc 2022-10-06 2022-10-06 /pmc/articles/PMC9561556/ /pubmed/36246828 http://dx.doi.org/10.12998/wjcc.v10.i28.10236 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Xu, Su-Zhen
Zhang, Xiao-Chen
Jiang, Qi
Chen, Ming
He, Meng-Ye
Shen, Peng
Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title_full Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title_fullStr Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title_full_unstemmed Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title_short Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
title_sort alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561556/
https://www.ncbi.nlm.nih.gov/pubmed/36246828
http://dx.doi.org/10.12998/wjcc.v10.i28.10236
work_keys_str_mv AT xusuzhen alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport
AT zhangxiaochen alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport
AT jiangqi alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport
AT chenming alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport
AT hemengye alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport
AT shenpeng alphafetoproteinproducinghepatoidadenocarcinomaofthelungresponsivetosorafenibaftermultilinetreatmentacasereport